Published in Neurosci Biobehav Rev on August 08, 2009
Does Propranolol Attenuate Inflammatory Responses to a Psychological Stressor? | NCT02972554
From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull (2014) 2.39
The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology (2011) 2.15
Stress, food, and inflammation: psychoneuroimmunology and nutrition at the cutting edge. Psychosom Med (2010) 1.22
Endotoxin-induced systemic inflammation activates microglia: [¹¹C]PBR28 positron emission tomography in nonhuman primates. Neuroimage (2012) 1.08
Synergistic relationships among stress, depression, and troubled relationships: insights from psychoneuroimmunology. Depress Anxiety (2013) 1.02
Glucose metabolism in the insula and cingulate is affected by systemic inflammation in humans. J Nucl Med (2012) 0.98
Citalopram reduces endotoxin-induced fatigue. Brain Behav Immun (2010) 0.97
Greater amygdala activity and dorsomedial prefrontal-amygdala coupling are associated with enhanced inflammatory responses to stress. Brain Behav Immun (2014) 0.96
Dose-dependent effects of endotoxin on neurobehavioral functions in humans. PLoS One (2011) 0.96
Maintenance of a positive outlook during acute stress protects against pro-inflammatory reactivity and future depressive symptoms. Brain Behav Immun (2011) 0.93
Interoceptive dysfunction: toward an integrated framework for understanding somatic and affective disturbance in depression. Psychol Bull (2014) 0.90
Preexisting mild sleep disturbance as a vulnerability factor for inflammation-induced depressed mood: a human experimental study. Transl Psychiatry (2016) 0.85
Kinin B1 receptors mediate depression-like behavior response in stressed mice treated with systemic E. coli lipopolysaccharide. J Neuroinflammation (2010) 0.85
Brain-immune interactions and the neural basis of disease-avoidant ingestive behaviour. Philos Trans R Soc Lond B Biol Sci (2011) 0.83
Relation between pro-inflammatory cytokines and acetylcholine levels in relapsing-remitting multiple sclerosis patients. Int J Mol Sci (2012) 0.83
Pre-treatment effects of peripheral tumors on brain and behavior: neuroinflammatory mechanisms in humans and rodents. Brain Behav Immun (2015) 0.81
Experimental human endotoxemia enhances brain activity during social cognition. Soc Cogn Affect Neurosci (2013) 0.81
The Involvement of TNF-α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments. Curr Neuropharmacol (2015) 0.79
Mast cells' involvement in inflammation pathways linked to depression: evidence in mastocytosis. Mol Psychiatry (2016) 0.79
Cytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation (tDCS): results from a factorial, randomized, controlled trial. Psychopharmacology (Berl) (2013) 0.79
Sex differences in the neuro-immune consequences of stress: Focus on depression and anxiety. Brain Behav Immun (2017) 0.79
Participation of brainstem monoaminergic nuclei in behavioral depression. Pharmacol Biochem Behav (2011) 0.77
A pre-conditioning stress accelerates increases in mouse plasma inflammatory cytokines induced by stress. BMC Neurosci (2015) 0.76
Brain CB₂ Receptors: Implications for Neuropsychiatric Disorders. Pharmaceuticals (Basel) (2010) 0.76
Selective increase of cerebrospinal fluid IL-6 during experimental systemic inflammation in humans: association with depressive symptoms. Mol Psychiatry (2017) 0.76
Changes in biologic markers of oxidative stress and plasma endotoxin levels in gynecologic cancer patients treated with pelvic radiotherapy: a pilot study. J Gynecol Oncol (2012) 0.75
Fracture as an independent risk factor of dementia: a nationwide population-based cohort study. Medicine (Baltimore) (2014) 0.75
Immune activation and neuroinflammation in alcohol use and HIV infection: evidence for shared mechanisms. Am J Drug Alcohol Abuse (2016) 0.75
Behavioral responses in rats submitted to chronic administration of branched-chain amino acids. JIMD Rep (2013) 0.75
Statin and Aspirin Use and the Risk of Mood Disorders among Men. Int J Neuropsychopharmacol (2016) 0.75
Exploring the boundaries of systemic inflammation*. Crit Care Med (2014) 0.75
Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry (2005) 58.92
Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet (1997) 25.40
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet (2009) 14.52
Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol (2009) 14.33
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry (2006) 14.15
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry (2006) 12.41
Inflammatory blockade restores adult hippocampal neurogenesis. Science (2003) 10.14
Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry (2009) 8.74
Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med (1988) 7.96
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med (2009) 7.06
The molecular neurobiology of depression. Nature (2008) 6.51
Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia (2007) 5.67
Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry (2001) 4.70
Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med (2001) 4.39
Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry (2006) 4.30
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet (2006) 4.26
Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am J Psychiatry (2009) 3.96
A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A (2003) 3.82
Excess mortality in depression: a meta-analysis of community studies. J Affect Disord (2002) 3.65
Food reward in the absence of taste receptor signaling. Neuron (2008) 3.37
Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry (2006) 3.33
Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol (2008) 3.30
Characteristics associated with delirium in older patients in a medical intensive care unit. Arch Intern Med (2007) 3.16
The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun (2001) 2.89
Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. Biol Psychiatry (2003) 2.77
Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun (2007) 2.75
Lipopolysaccharide signaling in endothelial cells. Lab Invest (2006) 2.58
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry (2006) 2.44
Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J ECT (2003) 2.41
The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun (2006) 2.40
Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry (2009) 2.33
Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev (2008) 2.30
Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J Neurosci (2009) 2.29
Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers. J Neurosci (2006) 2.22
TNF-alpha suppresses the expression of clock genes by interfering with E-box-mediated transcription. Proc Natl Acad Sci U S A (2007) 2.22
How (and why) the immune system makes us sleep. Nat Rev Neurosci (2009) 2.22
Gender differences in the innate immune response and vascular reactivity following the administration of endotoxin to human volunteers. Crit Care Med (2007) 2.18
Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: implications for fatigue. Brain Behav Immun (2007) 2.18
The cholinergic anti-inflammatory pathway. Brain Behav Immun (2005) 2.13
Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology (2007) 2.12
Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res (2006) 2.11
Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol (2006) 2.10
Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer (2005) 2.09
Exaggerated sickness behavior and brain proinflammatory cytokine expression in aged mice in response to intracerebroventricular lipopolysaccharide. Neurobiol Aging (2007) 2.03
Targeting innate immunity protein kinase signalling in inflammation. Nat Rev Drug Discov (2009) 2.01
Stress, depression, and anhedonia: caveats concerning animal models. Neurosci Biobehav Rev (2005) 2.00
Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry (2008) 1.96
Inflammatory markers in late-life depression: results from a population-based study. J Affect Disord (2007) 1.89
Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev (2005) 1.89
Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol Psychiatry (2008) 1.85
An fMRI study of cytokine-induced depressed mood and social pain: the role of sex differences. Neuroimage (2009) 1.79
Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut (2007) 1.75
Role of dopamine in the motivational and cognitive control of behavior. Neuroscientist (2008) 1.74
Acute inflammation and negative mood: mediation by cytokine activation. Brain Behav Immun (2004) 1.73
Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry (2009) 1.72
Tumor necrosis factor antagonism normalizes rapid eye movement sleep in alcohol dependence. Biol Psychiatry (2009) 1.72
Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab (1998) 1.70
Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol (2002) 1.67
Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord (1995) 1.65
Persistent depressive symptomatology and inflammation: to what extent do health behaviours and weight control mediate this relationship? Brain Behav Immun (2009) 1.63
Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology (2007) 1.63
Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog Neurobiol (2008) 1.61
Chronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer's disease. Brain Res (1998) 1.61
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther (2006) 1.59
Endotoxin-induced gene expression differences in the brain and effects of iNOS inhibition and norepinephrine. Intensive Care Med (2009) 1.59
Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry Neurosci (2009) 1.58
Recombinant human interferon-alpha does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats. Prog Neuropsychopharmacol Biol Psychiatry (2005) 1.56
Human endotoxemia: a model for mechanistic insight and therapeutic targeting. Shock (2005) 1.54
Neurohormonal-cytokine interactions: implications for inflammation, common human diseases and well-being. Neurochem Int (2007) 1.54
Neural origins of human sickness in interoceptive responses to inflammation. Biol Psychiatry (2009) 1.52
Major depression and all-cause mortality among white adults in the United States. Ann Epidemiol (1997) 1.50
Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology (1999) 1.49
A requirement for microglial TLR4 in leukocyte recruitment into brain in response to lipopolysaccharide. J Immunol (2006) 1.49
Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res (2006) 1.46
Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) (2003) 1.46
Metabotropic glutamate receptors mediate lipopolysaccharide-induced fever and sickness behavior. Brain Behav Immun (2005) 1.45
Cancer-related fatigue: links with inflammation in cancer patients and survivors. Brain Behav Immun (2007) 1.42
Neonatal infection-induced memory impairment after lipopolysaccharide in adulthood is prevented via caspase-1 inhibition. J Neurosci (2005) 1.41
Immunological effects of induced shame and guilt. Psychosom Med (2004) 1.40
Long-term cognitive impairment, neuronal loss and reduced cortical cholinergic innervation after recovery from sepsis in a rodent model. Exp Neurol (2007) 1.39
Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol (2006) 1.37
The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry (2001) 1.37
Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann N Y Acad Sci (1995) 1.36
Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol (2007) 1.34
Recombinant tumor necrosis factor and interleukin 1 enhance slow-wave sleep. Am J Physiol (1987) 1.33
Dissociating anorexia and anhedonia elicited by interleukin-1beta: antidepressant and gender effects on responding for "free chow" and "earned" sucrose intake. Psychopharmacology (Berl) (2002) 1.30
Inoculation of Bacillus Calmette-Guerin to mice induces an acute episode of sickness behavior followed by chronic depressive-like behavior. Brain Behav Immun (2008) 1.30
Behavioral effects of cytokines. Brain Behav Immun (2001) 1.29
Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord (2005) 1.29
Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals? J Affect Disord (2009) 1.28
Sleep disorders as core symptoms of depression. Dialogues Clin Neurosci (2008) 1.27
Dose-dependent effects of endotoxin on human sleep. Am J Physiol Regul Integr Comp Physiol (2000) 1.26
Endothelial-specific knockdown of interleukin-1 (IL-1) type 1 receptor differentially alters CNS responses to IL-1 depending on its route of administration. J Neurosci (2007) 1.25
The vagus nerve mediates behavioural depression, but not fever, in response to peripheral immune signals; a functional anatomical analysis. Eur J Neurosci (2000) 1.23
Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatr Scand (2007) 1.22
Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J Pain Symptom Manage (1993) 1.22
Appetite regulation: an overview. Thyroid (2007) 1.20
Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology (2001) 1.19
Endotoxin- or pro-inflammatory cytokine-induced sickness behavior as an animal model of depression: focus on anhedonia. Neurosci Biobehav Rev (2005) 1.16
Brain regulation of appetite and satiety. Endocrinol Metab Clin North Am (2008) 1.15
Rechallenging with clozapine following neutropenia: treatment options for refractory schizophrenia. Am J Psychiatry (2008) 2.40
Transcranial magnetic stimulation of Wernicke's and Right homologous sites to curtail "voices": a randomized trial. Biol Psychiatry (2013) 1.57
Neurotrophins and the immune system. J Anat (2003) 1.46
Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr (2008) 1.33
Sex differences in decreased limbic and cortical grey matter volume in cocaine dependence: a voxel-based morphometric study. Addict Biol (2012) 0.96
Identification, characterization, and gene expression profiling of endotoxin-induced myocarditis. Proc Natl Acad Sci U S A (2003) 0.96
Caspase 1 deficiency reduces inflammation-induced brain transcription. Proc Natl Acad Sci U S A (2007) 0.86
Bupropion pre-treatment of endotoxin-induced depressive symptoms. Brain Behav Immun (2012) 0.86
Regarding "depression and inflammation in patients with coronary heart disease: findings from the heart and soul study". Biol Psychiatry (2007) 0.76
Comment on "Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease". J Immunol (2010) 0.75